Inhibition of c-Jun N-terminal kinase, mitogen-activated protein kinase, and fibrosarcoma activation, downregulation of matrix metalloproteinase 2 secretion, and inhibition of cell migration and invasion in MDA-MB-453 breast cancer cells (HER2+). Here, ERBB2 is linked to breast carcinoma.